The Boston Institute of Biotechnology (BIB) specializes in providing comprehensive contract development and manufacturing organization (CDMO) services, focusing on both cGMP and non-GMP production across various platforms, including mammalian, microbial, gene therapy, and cell therapy. Their capabilities encompass a full spectrum of services, from cell line development and process characterization to analytical and formulation development. BIB boasts a state-of-the-art facility equipped with the world's first ultra-large bioreactor, capable of handling a working volume of 30,000 liters, which significantly enhances production efficiency and reduces costs. Their expertise extends to developing robust upstream and downstream processes for the production of recombinant proteins, viral vaccines, and gene therapies, ensuring high-quality results tailored to client needs.

In addition to their manufacturing capabilities, BIB emphasizes quality and compliance throughout the production process, leveraging decades of experience to deliver timely and competitive services. Their analytical development services include method optimization, assay qualification, and forced degradation studies, which are crucial for tracking yield and purity during production. BIB's innovative Blue Whale Program offers a financially risk-free manufacturing solution, streamlining construction and reducing costs for clients. With a commitment to providing high-quality, affordable medicines, BIB positions itself as a trusted partner in the biotechnology sector, dedicated to transforming molecules into effective treatments for patients.

United States

BIB is a full service CDMO partner offering cGMP and non-GMP mammalian, microbial, gene therapy and cell therapy services.

Boston Institute of Biotechnology

Company Details